Relay Therapeutics Inc (RLAY) - Total Assets
Based on the latest financial reports, Relay Therapeutics Inc (RLAY) holds total assets worth $699.61 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Relay Therapeutics Inc - Total Assets Trend (2018–2025)
This chart illustrates how Relay Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Also see RLAY market cap for the company's overall valuation and market capitalisation.
Relay Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Relay Therapeutics Inc's total assets of $699.61 Million consist of 93.1% current assets and 6.9% non-current assets. Review total liabilities of Relay Therapeutics Inc to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 13.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Relay Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See RLAY share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Relay Therapeutics Inc's current assets represent 93.1% of total assets in 2025, a decrease from 99.0% in 2018.
- Cash Position: Cash and equivalents constituted 13.5% of total assets in 2025, down from 98.3% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Relay Therapeutics Inc Competitors by Total Assets
Key competitors of Relay Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Relay Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 22.13 | 19.96 | 26.84 |
| Quick Ratio | 22.13 | 19.96 | 26.84 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $628.71 Million | $702.61 Million | $655.89 Million |
Relay Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Relay Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.93 |
| Latest Market Cap to Assets Ratio | 4.74 |
| Asset Growth Rate (YoY) | -28.7% |
| Total Assets | $621.33 Million |
| Market Capitalization | $2.95 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Relay Therapeutics Inc's assets at a significant premium (4.74x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Relay Therapeutics Inc's assets decreased by 28.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Relay Therapeutics Inc (2018–2025)
The table below shows the annual total assets of Relay Therapeutics Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $621.33 Million | -28.69% |
| 2024-12-31 | $871.30 Million | +3.24% |
| 2023-12-31 | $843.98 Million | -23.26% |
| 2022-12-31 | $1.10 Billion | +9.06% |
| 2021-12-31 | $1.01 Billion | +26.08% |
| 2020-12-31 | $799.83 Million | +103.48% |
| 2019-12-31 | $393.07 Million | -8.29% |
| 2018-12-31 | $428.61 Million | -- |
About Relay Therapeutics Inc
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clin… Read more